ACIP consideration of vaccine cost is appropriate in coverage decisions, CDC official testifies.

Executive Summary

ACIP CONSIDERATION OF VACCINE COST-BENEFIT IS APPROPRIATE, CDC's ORENSTEIN testified at a July 16 Senate Appropriations/Labor & HHS Subcommittee hearing on vaccines. "It is extremely important that [the Advisory Committee on Immunization Practices] take cost-benefit and cost effectiveness into account in their recommendations because...their recommendations go beyond what the government purchases. These are recommendations that basically address public health practices," Centers for Disease Control & Prevention National Immunization Program Director Walter Orenstein, MD, testified.